Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma: a Prospective, Randomized, Multi-center phaseIII-Trial

NCT00311467 is registered in ClinicalTrials.gov with Central European Cooperative Oncology Group as lead sponsor.

NCT NCT00311467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00311467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma: a Prospective, Randomized, Multi-center phaseIII-Trial
Lead sponsor
Central European Cooperative Oncology Group
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2004
Completion date
May 31, 2007
Enrollment
172 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell cancer